- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis (AD) significantly reduced patients’ reliance on other topical treatments, oral corticosteroids, and biologics in both biologic-experienced (n = 125) and biologic-naive (n = 431) populations, suggesting this Janus kinase (JAK) inhibitor may serve as an effective steroid-sparing agent with potential for long-term disease management across different patient subgroups.
EP: 1.Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
EP: 2.AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
EP: 3.Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
EP: 4.Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
EP: 5.JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks
EP: 6.From AAD 2025 to the Future: Advancements in Dermatology to Watch
- Now, let’s shift our focus to AD. and the emerging role of immune modulators in the treatment of AD. Please discuss the findings presented at AAD 2025 regarding the association of ruxolitinib cream initiation with a reduction in the use of other topical treatments, oral corticosteroids, and biologics for atopic dermatitis, regardless of previous use of biologics.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- n = 556
- n = 125 biologics during baseline period
- n = 431 no baseline biologic use
- Topical treatment use for AD before/after initiation of ruxolitinib cream
- Biologic-experienced
- Biologic naive
- Oral corticosteroid use before/after initiation of ruxolitinib cream
- Biologic-experienced
- Biologic naive
- Biologic use for AD before/after initiation of ruxolitinib cream
- n = 556
- What are your key takeaways from this study, and how do the results influence your perspective on long-term options for the treatment of atopic dermatitis?
- In your current practice, where does ruxolitinib fit in as a treatment option for atopic dermatitis, and how do you determine when to initiate? What are benefits and drawbacks that need to be considered when choosing immunomodulators such as JAK inhibitors for AD?
How has the use of immune modulators and biologics evolved over time, and how do you foresee the atopic dermatitis treatment paradigm changing moving forward?
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
